STEHealthcare · Medical DevicesThe 9 Wall Street analysts covering STERIS Plc (Ireland) hold a median 12-month price target of $257 — +10.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 1 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores STERIS Plc (Ireland) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Momentum (46): The shares have been drifting down relative to others.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own STERIS Plc (Ireland) — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on STE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | UBS | Initiates | Buy | $275 |
| 13 May 2026 | Keybanc | Maintains | Overweight | $291 → $269 |
| 13 May 2026 | Keybanc | Maintains | Overweight | — |
| 8 Aug 2025 | Morgan Stanley | Maintains | Overweight | — |
| 22 July 2025 | Keybanc | Maintains | Overweight | — |
| 15 July 2025 | Morgan Stanley | Upgrade | Overweight | — |
| 29 May 2025 | Jefferies | Initiates | Hold | — |
| 19 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 15 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 12 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 7 Apr 2025 | Needham | Reiterates | Hold | — |
| 6 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 6 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 3 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 18 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Nov 2024 | Needham | Reiterates | Hold | — |
| 7 Nov 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 24 Oct 2024 | Piper Sandler | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 33% of US stocks
Cheaper than 32% of US stocks
Cheaper than 24% of US stocks
Higher than 47% of US stocks
Higher than 78% of US stocks
Higher than 56% of US stocks
Higher than 80% of US stocks
Higher than 75% of US stocks
Higher than 67% of US stocks
Higher than 84% of US stocks
Higher than 25% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STE appears on the weeks it earns a place.
STERIS plc announced a quarterly interim dividend of $0.69 per share, a $0.06 increase, marking its 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record as of September 4, 2026.
Why it matters — The dividend increase and extended streak of consecutive dividend growth signal continued financial stability and a commitment to returning value to shareholders.
Zacks reported that STERIS is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.
Why it matters — The article highlights expected growth drivers across STERIS's key business segments, giving investors insight into what may influence the company's upcoming quarterly performance.
STERIS plc announced it will host a conference call on August 6, 2026, at 9:00 a.m. ET to discuss its fiscal 2027 first quarter results. The call will be available via webcast at steris-ir.com or by phone.
Why it matters — STE watchers will be interested because the conference call will provide management's discussion of the company's fiscal first quarter financial performance and outlook.
Seeking Alpha published an article describing Steris as a sterilization leader with 21 consecutive years of dividend increases, recent dividend growth above 10%, and a strong financial position with a low debt/equity ratio of 0.3 and interest coverage over 18.
Why it matters — The article highlights Steris's consistent dividend growth and solid financial health, which are key considerations for income-focused investors tracking STE.
The 9 Wall Street analysts covering STERIS Plc (Ireland) have a median 12-month price target of $257, with estimates ranging from $225 to $280. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering STERIS Plc (Ireland), 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks STERIS Plc (Ireland) 85 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, STERIS Plc (Ireland) ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +10.2% from the last close, and Ticker Nerd's factor model ranks STERIS Plc (Ireland) 85 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering STERIS Plc (Ireland) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $280 over the next 12 months.
STERIS Plc (Ireland) returned +3.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
STERIS plc is a global healthcare and life sciences company that provides infection prevention and other procedural products and services. The company focuses on helping hospitals, surgery centers, and other medical facilities maintain sterile, safe environments through a broad portfolio of capital equipment, consumables, and technical services.
The most recent item we track (GlobeNewsWire, 30 July 2026): "STERIS Raises Dividend to $0.69 per share". STERIS plc announced a quarterly interim dividend of $0.69 per share, a $0.06 increase, marking its 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record as of September 4, 2026.
STERIS plc is a global healthcare and life sciences company that provides infection prevention and other procedural products and services. The company focuses on helping hospitals, surgery centers, and other medical facilities maintain sterile, safe environments through a broad portfolio of capital equipment, consumables, and technical services. Its Healthcare-related offerings include sterilizers, washer-disinfectors, operating room and endoscopy workflow equipment, connectivity solutions, and infection-prevention chemistries and accessories, along with installation, maintenance, and repair services. Through its Applied Sterilization Technologies operations, STERIS supplies contract sterilization, laboratory testing, and packaging validation services to medical device and pharmaceutical manufacturers, supporting regulatory compliance in highly controlled settings. Its Life Sciences activities provide contamination-control equipment, sterilization and decontamination systems, and support services to biopharmaceutical, biotechnology, and research customers worldwide. Founded in 1985 and headquartered in Dublin, Ireland, with major operational presence in Mentor, Ohio, STERIS plc plays a central role in the infrastructure of modern healthcare and regulated manufacturing by enabling reliable infection prevention and sterile processing.
CEO Mr. Daniel A. Carestio · 17,937 employees · United States · https://www.steris.com